Quebec Pancreas Cancer Study (QPCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04104230|
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : February 23, 2021
|Condition or disease|
|Pancreas Cancer Pancreatic Cancer Pancreas Neoplasm Pancreas Cyst Pancreatic Precancerous Condition Familial Pancreatic Cancer Hereditary Cancer Bile Duct Cancer Ampullary Cancer Duodenal Cancer Gallbladder Cancer|
The objectives of the QPCS are as follows:
- To study the epidemiology of pancreas cancer, related cancers and related pre-cancerous conditions, including the risk factors and patient outcomes.
- To characterize the contribution of known hereditary cancer syndromes to pancreas cancer, related cancers, and related pre-cancerous conditions.
- To identify new genetic and epigenetic changes associated with hereditary pancreas cancer, related cancers, and related pre-cancerous conditions. DNA contains the instructions used in the development and functioning of living organisms, including humans. Epigenetic changes are changes other than changes in the underlying DNA sequence.
- To study the tumour biology of pancreas cancer and related pre-cancerous conditions. This may include studying the tumour and the environment surrounding the tumour, as well as blood and/or saliva samples. The studies may include characterization of genetic, genomic, transcriptomic, epigenetic, proteomic, and metabolomic changes.
- To identify and characterize biomarkers associated with pancreas cancer, related cancers and related pre-cancerous conditions.
- To determine if there are any epidemiological, clinical and outcome (for example, overall survival) associations with the genetic, genomic, epigenetic, transcriptomic, proteomic, metabolomic or other biologic changes that occur in pancreas cancer, related cancers and related pre-cancerous conditions.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||2000 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Quebec Pancreas Cancer Study|
|Actual Study Start Date :||March 12, 2012|
|Estimated Primary Completion Date :||January 2025|
|Estimated Study Completion Date :||January 2025|
Individuals Affected With Pancreatic Cancer
Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
Individuals Affected with Related Cancer
Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
Individuals Affected With Pancreatic Neoplasm
Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
- Knowledge and Tissue Bank [ Time Frame: 10 years ]Create a knowledge and tissue bank for pancreatic cancer, related pre-cancerous lesions, and related cancers, including patient demographics, type of chemotherapy treatments, type of surgical procedures, other procedures, overall survival, progression-free survival, epidemiological risk factors, genetic factors and characteristics of tumour tissue.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04104230
|Contact: Adeline Cuggia, MSc||514-934-1934 ext firstname.lastname@example.org|
|McGill University Health Centre||Recruiting|
|Montréal, Quebec, Canada, H4A 3J1|
|Contact: Adeline Cuggia, MSc 514-934-1934 ext 76333 email@example.com|
|Principal Investigator: George Zogopoulos, MD, PhD|
|Study Director:||George Zogopoulos, MD, PhD||McGill University Health Centre/Research Institute of the McGill University Health Centre|